SCHEMBL1015708

SCHEMBL1015708

Cc1nc(N2CCNCC2)ncc1C(=O)NC1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MAPT P10636 5/20 0.47
NR3C1 P04150 2/20 0.47
HSD11B1 P28845 1/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
LMNA P02545 1/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017870 0.91 POLB (0.64) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1014776 0.91 POLB (0.64) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1014028 0.89 POLB (0.61) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1013784 0.87 POLB (0.53) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1014719 0.87 POLB (0.53) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1015182 0.86 HSD11B1 (0.61) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1014425 0.86 HSD11B1 (0.61) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1014624 0.85 HSD11B1 (0.62) POLBSMN1; SMN2MAPTHSD11B1LMNA
SCHEMBL1014750 0.84 POLB (0.50) POLBSMN1; SMN2MAPTNR3C1HSD11B1
SCHEMBL1014757 0.83 PTPN11 (0.50) POLBSMN1; SMN2MAPTNR3C1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 POLB 2006/4885SMN1; SMN2 2203/4885MAPT 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.